Genmab — Oktober 2017
-
nobody does, there is something really wrong
-
-
0% growth ROW
-
Kan i uddybe lidt mere for os som ikke er så skarpe?
-
det er helt vildt skuffende
-
hvad havde i forventet og hvor stor er skuffelsen?
-
forventet var 360 - 370
-
der røg samtlige opjusteringer i år
-
der har den allerede været
-
Copenhagen, Denmark; October 17, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 317 million in the third quarter of 2017. Net sales were USD 230 million in the U.S. and USD 87 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind